DocGo Inc, also known as DCGO, is a leading provider in the burgeoning field of telehealth and mobile health services. The company is specialized in delivering on-demand, patient-centered, and mobile healthcare services to patients across the United States. DocGo was founded with a mission to revolutionize healthcare through the provision of innovative, reliable, and top-quality solutions.
DocGo combines a team of highly skilled medical professionals and technologists to provide on-the-spot medical care, including COVID-19 testing and vaccination services for individuals and facilities. Besides, the company offers various preventive, diagnostic, and treatment-related mobile healthcare services. One of their unique offerings includes their ambulance services, which are equipped with top-tier technology, allowing for remote doctor visits and care, even on the way to the clinic or hospital.
The company is also the developer of the innovative TeleHealth Plus, a system that allows patients to connect with healthcare professionals remotely, even if they're unable to travel to a traditional healthcare setting. This technology not only bridges the gap between patients and medical professionals but also increases medical access in underserved areas.
In terms of its financial track, DocGo went public in 2021 through a merger with Motion Acquisition Corp., a SPAC or special purpose acquisition company, reflecting the business's robust growth trajectory. This move was aimed to accelerate the firm’s growth strategy, enhance its leading market position and fund its financial requirements for advancements in technology while scaling up its operations.
The company, under the leadership of Stan Vashovsky, has disrupted the healthcare industry and ensured better continuity of care, from immediate medical response to aftercare. DocGo reflects a commitment made by a passionate group of health service professionals to deliver quality medical care anywhere, anytime, and redefine how care is delivered in the 21st century.
Amid the global health crisis, DCGO has seen an increase in demand and a major role in the fight against the pandemic. While they were already a key player in dispatching medical professionals and delivering mobile medical services, the pandemic only highlighted their importance in our healthcare model. The company has managed to exhibit a high level of preparedness, adaptability, and efficiency during these trying times. Therefore, DocGo embodies the future of healthcare—a future marked by the seamless blend of compassionate professionals, advanced technology, and efficient service delivery.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
DocGo has increased its estimated contingent consideration liability for the SteadyMD acquisition from $2.3 million to $5 million, reflecting a more optimistic revenue outlook for the telehealth business. This adjustment resulted in a $2.7 million fair-value loss in the first half but indicates an expected improvement in SteadyMD's performance. The stronger outlook for SteadyMD is crucial for DocGo as it faces declining revenues from migrant-related government programs, making growth from new businesses vital for future financial health and liquidity.
This article identifies three penny stocks—DocGo (DCGO), NET Power (NPWR), and Liquidmetal Technologies (LQMT)—for investors to watch in August 2026. Despite facing challenges typical of smaller companies like unprofitability and high volatility, these companies exhibit strong financial health indicators such as low debt and sufficient cash runways. The article advises investors to look for robust financials and clear growth trajectories in this segment.
Canaccord Genuity Group has reiterated its "Hold" rating for DocGo (NASDAQ:DCGO), maintaining a $1.00 price target, which implies an 85.9% upside from its current share price of $0.54. Analyst sentiment for DocGo is mixed, with a consensus "Hold" rating and an average target price of $2.38 among six analysts. DocGo's shares recently dropped 24.2% to $0.54, while institutional investors hold 56.44% of the company's stock.
Needham & Company LLC has reaffirmed its "buy" rating for DocGo (NASDAQ:DCGO) and set a price target of $3.00, suggesting a potential upside of 322.48% from its current price. Despite this, the stock has an overall "Hold" rating from analysts with an average price target of $2.38. DocGo is an integrated healthcare company providing on-demand and mobile healthcare services through customized medical clinics and a digital care platform.
DocGo (NASDAQ:DCGO) shares dropped significantly after the company reported weaker-than-expected second-quarter 2026 results and substantially increased its projected full-year adjusted EBITDA loss. The mobile healthcare provider's revenue was impacted by the wind-down of migrant-related contracts, and its profitability outlook worsened, leading to investor concern. The acquisition of Hicuity Health also adds integration risk while the company faces a negative market backdrop and Nasdaq listing compliance issues.
DocGo Inc. reported a wider-than-expected diluted loss of $0.16 per share for Q2 2026 and revenue of $73.4 million, falling short of analyst expectations. The company attributes the miss to its restructuring efforts away from migrant services, though core operations excluding migrant programs showed a 19% revenue climb. DocGo provided full-year revenue guidance between $305.0 million and $310.0 million, and analyst consensus remains cautiously balanced with 4 buys and 4 holds.